Antibody Response after Homologous and Heterologous Prime–Boost COVID-19 Vaccination in a Bangladeshi Residential University Cohort
Vaccines · 30.04.2024 · 12 (5) · 482
DOI: 10.3390/vaccines12050482 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vaccines, online erschienen am 30.04.2024. Verfasst von Nihad Adnan und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Jahangirnagar University, Savar, Dhaka 1342, Bangladesh. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
COVID-19 vaccination strategies, including heterologous prime–boost regimens and additional booster doses, aim to optimize immune responses. However, seroepidemiological studies on immune responses to different COVID-19 vaccine types and schedules remain limited. This study investigated antibody levels following homologous and heterologous prime-and-boost COVID-19 vaccination in Bangladesh. In a cohort of 606 participants who received first/second/booster doses of vaccines (AstraZeneca, Moderna, Pfizer-BioNTech, and Sinopharm), anti-spike IgG and anti-nucleocapsid IgG levels were measured. Antibody titer variations with respect to age, gender, intervals between doses, and prior infection status were analyzed. mRNA vaccines elicited the highest antibody levels after homologous and heterologous boosting. The AstraZeneca booster resulted in a sharp titer decline rate of ~0.04 units per day. Second or booster vaccine doses significantly increased antibody levels, especially in males (p < 0.05). Older age correlated with higher titers, likely reflecting previous infection, which was further confirmed by the elevation of anti-nucleocapsid IgG levels. About 95.5% of non-Sinopharm recipients were anti-nucleocapsid IgG positive, suggesting prior exposure exceeding self-reported infections (12.5%). mRNA and heterologous COVID-19 boosting enhances humoral immunity over homologous prime–boost vector/inactivated vaccination. However, waning immunity merits further investigation across vaccine platforms.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Microbiology, Jahangirnagar University, Savar, Dhaka 1342, Bangladesh.
- RNA Biotech Limited, Dhaka 1209, Bangladesh.
- Gonoshasthaya-RNA Biotech Limited, Dhaka 1205, Bangladesh.
- Institute of Quantitative Biology, Biochemistry and Biotechnology, School of Biological Sciences, University of Edinburgh, Edinburgh EH9 3FF, UK.
- Department of Pharmacy, Jahangirnagar University, Savar, Dhaka 1342, Bangladesh.
- School of Pharmacy, BRAC University, Dhaka 1212, Bangladesh.
ORCID-Profile: Nihad Adnan, Md Ahsanul Haq, Salma Akter, Mohd Raeed Jamiruddin, Md Salequl Islam, Jamsheda Ferdous Tuli, Sharif Hossain, Shahad Saif Khandker, Rubel Hossain, Md Anowar Khasru Parvez
Zitieren
APA
Adnan, N., Haq, M. A., Akter, S., Sajal, S. M. S. A., Islam, M. F., Mou, T. J., Jamiruddin, M. R., Jubyda, F. T., Islam, M. S., Tuli, J. F., Liza, S. M., Hossain, S., Islam, Z., Ahmed, S., Khandker, S. S., Hossain, R., Ahmed, M. F., Khondoker, M. U., Azmuda, N., & Parvez, M. A. K. (2024). Antibody Response after Homologous and Heterologous Prime–Boost COVID-19 Vaccination in a Bangladeshi Residential University Cohort. Vaccines, 12(5), 482. https://doi.org/10.3390/vaccines12050482
Vancouver
Adnan N, Haq MA, Akter S, Sajal SMSA, Islam MF, Mou TJ, et al. Antibody Response after Homologous and Heterologous Prime–Boost COVID-19 Vaccination in a Bangladeshi Residential University Cohort. Vaccines. 2024;12(5):482. doi:10.3390/vaccines12050482
BibTeX
@article{Adnan2024,
author = {Adnan, Nihad and Haq, Md Ahsanul and Akter, Salma and Sajal, S M Shafiul Alam and Islam, Md Fokhrul and Mou, Taslin Jahan and Jamiruddin, Mohd Raeed and Jubyda, Fatema Tuz and Islam, Md Salequl and Tuli, Jamsheda Ferdous and Liza, Syeda Moriam and Hossain, Sharif and Islam, Zinia and Ahmed, Sohel and Khandker, Shahad Saif and Hossain, Rubel and Ahmed, Md Firoz and Khondoker, Mohib Ullah and Azmuda, Nafisa and Parvez, Md Anowar Khasru},
title = {Antibody Response after Homologous and Heterologous Prime–Boost COVID-19 Vaccination in a Bangladeshi Residential University Cohort},
journal = {Vaccines},
year = {2024},
volume = {12},
number = {5},
pages = {482},
doi = {10.3390/vaccines12050482}
}
EUVIMED